Uveitis Clinical Trial
This study will investigate the safety and effectiveness of the drug Enbrel (TNFR:Fc) to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.
In other studies, TNFR:Fc significantly reduced joint pain and swelling in adult patients
with rheumatoid arthritis, and the Food and Drug Administration has approved the drug for
that use. Because medicines for arthritis often help patients with eye inflammation, this
study will examine whether TNFR:Fc can help patients with uveitis.
Patients with uveitis who are not responding well to standard treatment, such as steroids,
and patients who have side effects from other medicines used to treat their uveitis or have
refused treatment because of possible side effects may be eligible for this study.
Candidates will be screened with a medical history, physical examination, and eye
examination. The eye exam includes a check of vision and eye pressure, examination of the
back of the eye (retina), and front of the eye, including measurements of protein and
inflammation. Candidates will also undergo fluorescein angiography-a procedure in which
photographs are taken of the retina to see if there is any leakage in the eye's blood
vessels. A blood test and joint evaluation will also be done.
Study participants will be given an injection of TNFR:Fc twice a week for up to 12 months
and may continue other medicines they may be taking, such as prednisone or methotrexate.
They will have follow-up examinations at week two and months one, two, three and four. Those
who wish to continue treatment after the fourth month can receive the drug for another eight
months and will have follow-up exams at months six, nine and 12, and one month after
treatment ends. Each follow-up visit will include a repeat of the screening exams and an
evaluation of side effects or discomfort from the medicine.
;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
| Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
| Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
| Withdrawn |
NCT01280669 -
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
|
Phase 2 | |
| Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
| Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
| Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
| Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
| Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
| Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
| Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
| Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
| Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
| Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
| Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
| Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
| Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
| Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
| Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|